文献速递生殖医学产科

随机启动卵巢刺激用于生育力保存似乎不太可能延迟乳腺癌新辅助化疗的启动

Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
PubMed 文献 · Hum Reprod · 2017-01-01

这项横断面研究纳入2011年1月至2017年4月在新辅助化疗前接受生育力保存咨询的89例乳腺癌女性,67%接受了卵巢刺激,33%未接受。接受与未接受卵巢刺激者从癌症诊断到化疗启动的平均时间相似(38.1±11.3天 vs 39.4±18.5天,P=0.672)。

要点

  • 接受卵巢刺激者与未接受者从诊断到化疗启动时间相似(38.1±11.3天 vs 39.4±18.5天,P=0.672)。
  • 接受卵巢刺激者诊断后转诊更早(9.4±6.8天 vs 17.9±15.3天,P<0.001)。
  • 只要生育力保存转诊及时,随机启动卵巢刺激未 associated with 延迟新辅助化疗。

核心结论

  • 在完成生育力保存咨询的女性中,随机启动卵巢刺激似乎不太可能延迟新辅助化疗的启动。

研究设计与样本

  • 横断面研究,纳入2011年1月至2017年4月在新辅助化疗前接受生育力保存咨询的全部女性,共识别89例。
  • 纳入标准为女性、年龄18-45岁、非转移性乳腺癌诊断、接受生育力保存咨询、接受新辅助化疗。
  • 采用病历回顾获取与癌症诊断、生育力保存或化疗相关的多个时间点,使用T检验和线性模型比较接受与未接受卵巢刺激者的时间点。

主要发现

  • 67%在癌症治疗前接受卵巢刺激,33%未接受。
  • 接受卵巢刺激者与未接受者在产次和临床癌症分期上相似。
  • 从癌症诊断到化疗启动的平均时间在接受卵巢刺激组与未接受组之间相似(38.1±11.3天 vs 39.4±18.5天,P=0.672)。
  • 接受卵巢刺激者在诊断后9.4±6.8天转诊,未接受卵巢刺激者为17.9±15.3天(P<0.001)。

临床怎么用

  • 作者认为,只要生育力保存转诊及时,在新辅助治疗背景下随机启动卵巢刺激的生育力保存与癌症治疗延迟无关。
  • 作者认为,应告知接受新辅助化疗的患者这些发现,以避免因担心延迟而产生不必要的焦虑。

局限性

  • 回顾性研究,接受与未接受卵巢刺激者之间可能存在选择偏倚。
  • 需谨慎的原因包括接受与未接受卵巢刺激者之间可能存在未测量的差异,包括患者和提供者对开始化疗紧迫性的看法、正在进行的肿瘤学检查和治疗计划、生育力保存决策以及寻求第二和第三意见。
  • 从转诊到生育力保存咨询的时间差异也可能影响患者关于是否接受卵巢刺激的决定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is random start ovarian stimulation associated with delays in initiation of neoadjuvant chemotherapy for breast cancer? SUMMARY ANSWER: Among women who complete fertility preservation (FP) consultation, random start ovarian stimulation is unlikely to delay time to initiation of neoadjuvant chemotherapy start. WHAT IS KNOWN ALREADY: Neoadjuvant chemotherapy is now a widely accepted treatment modality for operable breast cancer and random start ovarian stimulation is an increasingly-utilized modality for FP. While conventional ovarian stimulation does not appear to delay starting adjuvant chemotherapy, the relationship between random start ovarian stimulation and neoadjuvant chemotherapy start is not well-understood. STUDY DESIGN, SIZE, DURATION: Cross-sectional study of all women seen between from January 2011 to April 2017 for FP consultation prior to starting neoadjuvant chemotherapy for breast cancer. PARTICIPANTS/MATERIALS, SETTING, METHODS: A chart-review was performed. Study inclusion criteria were female sex; age 18-45; non-metastatic breast cancer diagnosis; underwent FP consultation; underwent neoadjuvant chemotherapy. Referrals for FP evaluation came from a regional referral base of oncology clinics. Various time-points related to cancer diagnosis, FP or chemotherapy were obtained from medical record review. We compared time-points between those who underwent ovarian stimulation for FP versus those who did not using T-tests and linear modeling. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 89 women who had FP consultation prior to neoadjuvant chemotherapy were identified. Sixty-seven percent underwent ovarian stimulation prior to cancer treatment and 33% did not. Women who underwent ovarian stimulation were similar in parity and clinical cancer stage to those who did not. Overall, the average time from cancer diagnosis to chemotherapy start was similar between the group that did undergo ovarian stimulation and those who did not (38.1 ± 11.3 versus 39.4 ± 18.5 days, P = 0.672). Those that underwent ovarian stimulation were referred 9.4 ± 6.8 days after diagnosis versus 17.9 ± 15.3 days for those who did not undergo ovarian stimulation (P < 0.001). LIMITATIONS REASONS FOR CAUTION: Retrospective study with potential for selection bias among those who underwent ovarian stimulation versus those who did not. Reasons for caution include the possibility of unmeasured differences among those who did and did not undergo ovarian stimulation, including: patients' and providers' perceptions of the urgency to start chemotherapy, ongoing oncology work-up and treatment planning, FP decision-making, and the pursuit of second and third opinions. The difference in time from referral to FP consultation may have also influenced patients' decisions about whether to undergo ovarian stimulation. WIDER IMPLICATIONS OF THE FINDINGS: In this study, FP with random start ovarian stimulation was not associated with a delay cancer treatment in the neoadjuvant setting, so long as there was a prompt FP referral. Patients undergoing neoadjuvant chemotherapy should be informed of these findings to avoid unnecessary anxiety due to concern for delays. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by departmental research funding within the University of California, San Francisco Department of Obstetrics, Gynecology and Reproductive Sciences. There are no conflicts of interest to declare.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Letourneau JM, Sinha N, Wald K, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017. PMID: 28938748. doi:10.1093/humrep/dex276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。